James Crowe Jr.

Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.
January 24, 2019

VUMC scientists ‘sprint’ to find anti-Zika antibodies

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

By Bill Snyder
December 6, 2018

Discovery could lead to neutralizing West Nile virus

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

By Bill Snyder
October 18, 2018

Translational Research Forum set for Oct. 26

Patricia Griffin, MD, chief of the Enteric Diseases Epidemiology Branch at the U.S. Centers for Disease Control and Prevention (CDC), will be the guest speaker at the 2018 Vanderbilt Translational Research Forum Oc. 26 at the Vanderbilt Student Life Center.

By Bill Snyder
October 11, 2018

Symposium to focus on prospects for a universal flu vaccine

Internationally known vaccine experts including Vanderbilt University’s James Crowe Jr., MD, will speak next month at a symposium in Nashville on prospects for a universal flu vaccine.

By Bill Snyder
August 30, 2018

Team isolates antibodies that neutralize GI bug norovirus

Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies that can neutralize norovirus, the leading cause of acute gastrointestinal illness in the world.

By Bill Snyder
July 19, 2018

Team finds potent antibodies against three Ebola viruses

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.

By Bill Snyder
May 21, 2018

New target to stop Ebola

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.
By VUMC News and Communications
May 17, 2018

Alphavirus “Achilles heel”

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.
By Bill Snyder
April 26, 2018

Study seeking to isolate antibodies against rabies virus

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.
By Bill Snyder
April 12, 2018

Research lab honored by World Vaccine Congress

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.
By Bill Snyder
February 23, 2018

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.
By Bill Snyder
January 11, 2018

VUMC joins national effort to block global pandemics of potentially lethal viruses

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.
By Bill Snyder
December 14, 2017

Crowe elected a fellow of the National Academy of Inventors

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI).
By Bill Snyder
1 … 3 4 5 6 7 … 9